Chronic Lymphocytic Leukemia

Latest News

August 10th 2020

Dr. Ghia on Lack of OS Advantage With Acalabrutinib Per ASCEND Trial in CLL

Paolo Ghia, MD, PhD, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial.

Latest Videos

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL and Other Hematologic Malignancies

A Real-World Case of a Patient with CLL and a Cardiac History

Strategies for Managing Atrial Fibrillation in Patients on BTKi

Dr. Danilov on the Rationale to Combine Entospletinib With Obinutuzumab in CLL

Balancing the Risk and Benefit of Anticoagulation in Patients on BTKi

Baseline Testing Prior to Initiation of BTKi Treatment in CLL

Key Safety Considerations

A Review of Treatment Options in CLL

Dr. Wierda on the Safety and Efficacy Results of the TRANSCEND CLL 004 Trial in CLL

Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center

Dr. Thompson on the Results of the BRUIN Study in Patients With Richter's Transformation

CME Content

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Video

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Geoffrey Ku, MD; Jack W. Erter III, MD, MMHC

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Syma Iqbal, MD; Benjamin Scheier, MD

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Sunnie S. Kim, MD; Kellie D. Spector, MD

Video

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Amy E. Armstrong, MD; Phioanh “Leia” Nghiemphu, MD

Virtual Event

Kansas Society of Clinical Oncology

1 Session is Available!

Video

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

Daniela A. Bota, MD, PhD; Kurt C. Demel, MD, MBA

Video

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Video

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Daniela A. Bota, MD, PhD; Benjamin Scheier, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP

Virtual Event

Tennessee Oncology Practice Society

2 Sessions are Available!

Virtual Event

Washington State Medical Oncology Society

2 Sessions are Available!

Virtual Event

Louisiana Oncology Society

3 Sessions are Available!

Video

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Video

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Video

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Video

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Video

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

Video

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

Multimedia

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Video

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Video

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Video

Optimizing Multidisciplinary Care in TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Video

Diagnosis and Management of TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Video

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Video

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Video

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Archan Khandekar, MD; Wassim Kassouf, MD, CM, FRCSC; Jen-Jane Liu, MD

Multimedia

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

John V. Heymach, MD, PhD; Anne S. Tsao, MD, MBA, FASCO, FACHE

Video

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Aakash Desai, MD, MPH; Ibiayi Dagogo-Jack, MD, FASCO; Patrick Forde, MD, PhD

Video

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

Video

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD

Video

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

More News

PI3 Kinase Inhibitors in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Therapeutic Sequencing in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK Inhibitors in Relapsed/Refractory CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

MURANO Trial Update in R/R CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Utility of MRD Testing in CLL Management

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Venetoclax Combinations, Safety and Efficacy

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Venetoclax and Obinutuzumab in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Novel Therapies for Relapsed/Refractory CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Relapsed/Refractory CLL: Treatment Selection

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK inhibitor With vs Without a CD20-Targeted Antibody

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Second-Generation BTK Inhibitors in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Therapies in the Pipeline for Frontline CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Telemedicine for Patients With CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK Inhibitors in CLL: Ibrutinib

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Treating CLL During COVID-19

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Frontline Treatment Options in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Selecting Frontline Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

COVID-19 and CLL Treatment Initiation

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Selecting First-Line Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Advances in Frontline Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Impact of COVID-19 on Management of CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

EU Panel Recommends Ibrutinib/Rituximab Combo for Frontline CLL

ByKristi Rosa

July 24th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for ibrutinib in combination with rituximab for use in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Al-Sawaf on Continual MRD Assessment After Venetoclax/Obinutuzumab in CLL

ByOthman Al-Sawaf, MD

July 20th 2020

Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.